- In December 2023, Neurocrine Biosciences received Breakthrough Therapy designation from the FDA for its crinecerfont treatment aimed at congenital adrenal hyperplasia (CAH). This designation acknowledges the promising potential of crinecerfont in treating CAH, a rare endocrine disorder affecting hormone production. The FDA's recognition accelerates its development, facilitating faster access to critical treatments for patients suffering from this genetic disorder, which can lead to severe hormonal imbalances
- In March 2023, Oregon State University College of Engineering introduced a handheld sensor capable of testing cortisol levels in perspiration within just eight minutes. This development marks a significant leap in hormone monitoring, offering a non-invasive, rapid method to assess stress hormone levels. Such technology could revolutionize medical diagnostics by providing real-time, convenient monitoring for conditions such as Addison's disease and Cushing's syndrome, improving patient care and management
- In April 2022, Diurnal Group expanded its distribution agreement with Er-Kim to include Greece, Cyprus, and Malta. The expanded agreement involves the marketing and distribution of Alkindi and Efmody, medications used to treat Addison's disease. This strategic move aims to improve patient access to these critical treatments in the region, addressing the need for effective therapies for adrenal insufficiency and supporting patients with lifelong hormonal disorders
- In January 2022, Antares Pharma received Fast Track designation from the FDA for ATRS-1902, a medication designed for adrenal crisis rescue in both adults and adolescents. The drug, delivered via the Vai auto-injector platform, is a stable liquid hydrocortisone formulation that offers a more efficient solution for managing adrenal crises. This designation highlights the urgent need for accessible treatments and speeds up ATRS-1902's development to meet this critical healthcare gap
- In November 2020, Spruce Biosciences announced positive Phase 2 trial results for tildacerfont, a treatment under evaluation for congenital adrenal hyperplasia (CAH), a condition often linked with Addison's disease. The trial’s success offers hope for expanding treatment options for CAH, a rare disorder that impairs adrenal function. The results suggest tildacerfont could become a valuable therapeutic option, potentially providing better hormonal regulation for individuals affected by CAH
- In April 2020, The FDA approved Recorlev (levoketoconazole) for the treatment of endogenous Cushing's syndrome, a disorder that can sometimes overlap with Addison's disease. This approval marks a significant advancement in treating adrenal dysfunctions by offering a new option for patients with Cushing’s syndrome, which involves excessive cortisol production. Recorlev’s approval provides an essential alternative for patients managing overlapping symptoms of both Cushing’s syndrome and Addison’s disease
Frequently Asked Questions
The market is segmented based on Global Addison's Disease Drugs Market Segmentation, By Diagnosis (Laboratory Tests and Image Testing), Treatment (Oral Corticosteroid and Corticosteroid Injections), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others) – Industry Trends and Forecast to 2032
.
The Global Addisons Disease Drugs Market size was valued at USD 674.61 USD Million in 2024.
The Global Addisons Disease Drugs Market is projected to grow at a CAGR of 10.5% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
